These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 31720448)
1. Development of a specific IgY-based ELISA for prothymosin alpha, a bioactive polypeptide with diagnostic and therapeutic potential. Karachaliou CE; Kostopoulos IV; Vassilakopoulou V; Klimentzou P; Paravatou-Petsotas M; Voelter W; Kalbacher H; Zikos C; Tsitsilonis O; Livaniou E Heliyon; 2019 Oct; 5(10):e02616. PubMed ID: 31720448 [TBL] [Abstract][Full Text] [Related]
2. Development of an ELISA for the quantification of the C-terminal decapeptide prothymosin α(100-109) in sera of mice infected with bacteria. Samara P; Kalbacher H; Ioannou K; Radu DL; Livaniou E; Promponas VJ; Voelter W; Tsitsilonis O J Immunol Methods; 2013 Sep; 395(1-2):54-62. PubMed ID: 23831611 [TBL] [Abstract][Full Text] [Related]
3. Prothymosin Alpha and Immune Responses: Are We Close to Potential Clinical Applications? Samara P; Ioannou K; Tsitsilonis OE Vitam Horm; 2016; 102():179-207. PubMed ID: 27450735 [TBL] [Abstract][Full Text] [Related]
4. In Vitro Immunodetection of Prothymosin Alpha in Normal and Pathological Conditions. Karachaliou CE; Kalbacher H; Voelter W; Tsitsilonis OE; Livaniou E Curr Med Chem; 2020; 27(29):4840-4854. PubMed ID: 31389310 [TBL] [Abstract][Full Text] [Related]
5. Specific in vitro binding of a new (99m)Tc-radiolabeled derivative of the C-terminal decapeptide of prothymosin alpha on human neutrophils. Karachaliou CE; Liolios C; Triantis C; Zikos C; Samara P; Tsitsilonis OE; Kalbacher H; Voelter W; Papadopoulos M; Pirmettis I; Livaniou E Int J Pharm; 2015; 486(1-2):1-12. PubMed ID: 25796124 [TBL] [Abstract][Full Text] [Related]
6. Development and immunochemical evaluation of antibodies Y for the poorly immunogenic polypeptide prothymosin alpha. Klimentzou P; Paravatou-Petsotas M; Zikos C; Beck A; Skopeliti M; Czarnecki J; Tsitsilonis O; Voelter W; Livaniou E; Evangelatos GP Peptides; 2006 Jan; 27(1):183-93. PubMed ID: 16150512 [TBL] [Abstract][Full Text] [Related]
7. Immunocytological and preliminary immunohistochemical studies of prothymosin alpha, a human cancer-associated polypeptide, with a well-characterized polyclonal antibody. Klimentzou P; Drougou A; Fehrenbacher B; Schaller M; Voelter W; Barbatis C; Paravatou-Petsotas M; Livaniou E J Histochem Cytochem; 2008 Nov; 56(11):1023-31. PubMed ID: 18711212 [TBL] [Abstract][Full Text] [Related]
8. Prothymosin Alpha: An Alarmin and More.. Samara P; Karachaliou CE; Ioannou K; Papaioannou NE; Voutsas IF; Zikos C; Pirmettis I; Papadopoulos M; Kalbacher H; Livaniou E; Tsitsilonis OE; Voelter W Curr Med Chem; 2017; 24(17):1747-1760. PubMed ID: 28521686 [TBL] [Abstract][Full Text] [Related]
9. Prothymosin α and its C-Terminal Immunoreactive Decapeptide Show No Evidence of Acute Toxicity: A Preliminary Birmpilis AI; Vitsos P; Kostopoulos IV; Williams L; Ioannou K; Samara P; Karachaliou CE; Voutsas IF; Alyfanti E; Angelis N; Gavalas NG; Gkraikou T; Kappa N; Klagkou E; Klimentzou P; Nikou S; Papaioannou NE; Skopeliti M; Toukli D; Dimopoulos MA; Bamias A; Livaniou E; Kalbacher H; Tsitsilonis OE; Voelter W Curr Med Chem; 2022; 29(42):6463-6478. PubMed ID: 34789121 [TBL] [Abstract][Full Text] [Related]
10. The immunologically active site of prothymosin alpha is located at the carboxy-terminus of the polypeptide. Evaluation of its in vitro effects in cancer patients. Skopeliti M; Voutsas IF; Klimentzou P; Tsiatas ML; Beck A; Bamias A; Moraki M; Livaniou E; Neagu M; Voelter W; Tsitsilonis OE Cancer Immunol Immunother; 2006 Oct; 55(10):1247-57. PubMed ID: 16453152 [TBL] [Abstract][Full Text] [Related]
11. Antitumor Reactive T-Cell Responses Are Enhanced In Vivo by DAMP Prothymosin Alpha and Its C-Terminal Decapeptide. Birmpilis AI; Karachaliou CE; Samara P; Ioannou K; Selemenakis P; Kostopoulos IV; Kavrochorianou N; Kalbacher H; Livaniou E; Haralambous S; Kotsinas A; Farzaneh F; Trougakos IP; Voelter W; Dimopoulos MA; Bamias A; Tsitsilonis O Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717548 [TBL] [Abstract][Full Text] [Related]
12. A fragment of the alarmin prothymosin α as a novel biomarker in murine models of bacteria-induced sepsis. Samara P; Miriagou V; Zachariadis M; Mavrofrydi O; Promponas VJ; Dedos SG; Papazafiri P; Kalbacher H; Voelter W; Tsitsilonis O Oncotarget; 2017 Jul; 8(30):48635-48649. PubMed ID: 28611290 [TBL] [Abstract][Full Text] [Related]
13. In vivo biodistribution and imaging studies with a Karachaliou CE; Triantis C; Liolios C; Palamaris L; Zikos C; Tsitsilonis OE; Kalbacher H; Voelter W; Loudos G; Papadopoulos M; Pirmettis I; Livaniou E Eur J Pharm Biopharm; 2017 Apr; 113():188-197. PubMed ID: 28087377 [TBL] [Abstract][Full Text] [Related]
16. Prothymosin-alpha plays a defensive role in retinal ischemia through necrosis and apoptosis inhibition. Fujita R; Ueda M; Fujiwara K; Ueda H Cell Death Differ; 2009 Feb; 16(2):349-58. PubMed ID: 18989338 [TBL] [Abstract][Full Text] [Related]
17. Prothymosin α interacts with SET, ANP32A and ANP32B and other cytoplasmic and mitochondrial proteins in proliferating cells. Barbeito P; Sarandeses CS; Díaz-Jullien C; Muras J; Covelo G; Moreira D; Freire-Cobo C; Freire M Arch Biochem Biophys; 2017 Dec; 635():74-86. PubMed ID: 29106904 [TBL] [Abstract][Full Text] [Related]
18. Prothymosin alpha as robustness molecule against ischemic stress to brain and retina. Ueda H; Matsunaga H; Uchida H; Ueda M Ann N Y Acad Sci; 2010 Apr; 1194():20-6. PubMed ID: 20536446 [TBL] [Abstract][Full Text] [Related]
20. Prothymosin alpha and cell death mode switch, a novel target for the prevention of cerebral ischemia-induced damage. Ueda H Pharmacol Ther; 2009 Sep; 123(3):323-33. PubMed ID: 19500618 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]